BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of BCX9930 monotherapy for
the treatment of PNH compared to continued C5 inhibitor therapy in adult PNH patients with
residual anemia despite treatment with a C5 inhibitor.